Simcast News Portal

Real-world effectiveness and safety of blinatumomab in adults with B-cell precursor acute lymphoblastic leukaemia across 13 European countries - Blood Cancer Journal

Nature

Last updated: May 3, 2026

Blinatumomab, a bispecific T-cell engager (BiTE®), targets CD19 and CD3 to activate T-cells against cancer. It is an established immunotherapy for patients with measurable residual disease-positive (MRD+) and relapsed/refractory (R/R) Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL). Recent research explores its efficacy and safety in specific patient subgroups and its potential role in different treatment settings.

The text discusses blinatumomab's role in treating B-ALL, particularly for MRD+ and R/R patients.
It highlights blinatumomab as a standard of care for these conditions, demonstrating efficacy in achieving remission and improving outcomes.
The article likely explores clinical trial data, focusing on response rates, survival data, and event-free survival in patients treated with blinatumomab.
Safety and tolerability are key aspects, with a review of common adverse events and strategies for managing them, such as cytokine release syndrome (CRS) and neurological toxicities.
The text may also touch upon blinatumomab's use in various lines of therapy, including consolidation and maintenance, and its potential combinations with other treatments to enhance efficacy.
Comparisons with other therapeutic options, such as chemotherapy or stem cell transplantation, might be included to contextualize blinatumomab's benefits and limitations.
Further investigation into factors predicting response to blinatumomab and personalized treatment approaches could also be a focus.
The overall aim is to provide an updated, comprehensive overview of blinatumomab's clinical utility in B-ALL management.